Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and PK of Sirukumab in Healthy Males
NCT02079545Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2014
- Primary completion
- Jan 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sirukumab in rheumatoid arthritis (RA) (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Absolute bioavailability of 100 mg sirukumab administered subcutaneously, Maximum Observed Serum Concentration and 1 more. Started Mar 2014; status: completed.
02
Drugs
sirukumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02079545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02079545.